title: Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion.
abstract: OBJECTIVE
  To evaluate the retinal toxicity of intravitreal tissue plasminogen activator (tPA) injection for branch and central retinal vein occlusion (BRVO and CRVO) using the electroretinogram (ERG).
  
  
  METHODS
  Ten BRVO patients and 5 CRVO patients were enrolled. A complete examination including full-field ERG, visual acuity, central retinal thickness (CRT), and evaluation of systemic and ocular complications was performed before and after intravitreal tPA injection.
  
  
  RESULTS
  No significant differences were found in the amplitude or implicit time of any ERG component after tPA injection, and no systemic or ocular complication was observed. The improvement of visual acuity was significant at month 3 in the BRVO group (p < 0.05) but not in the CRVO group. CRT significantly decreased over the course of 3 months in both groups (p < 0.01).
  
  
  CONCLUSIONS
  Intravitreal tPA injection seems to be a safe and effective treatment option for macular oedema caused by retinal vein occlusions.
authors.affiliation: Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: Mizuki
authors.initials: M
authors.lastname: Tagami
authors.forename: Sentaro
authors.initials: S
authors.lastname: Kusuhara
authors.forename: Hisanori
authors.initials: H
authors.lastname: Imai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Honda
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Tsukahara
authors.forename: Akira
authors.initials: A
authors.lastname: Negi
mesh_terms: D000368:Aged; D004596:Electroretinography / Q000187:drug effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator